Picterus key facts
as of Oct 2026- Developer of a smartphone-based neonatal screening tool designed for early detection of jaundice in newborns.
- Picterus is valued at approximately $8.9M as of Oct 2026 (last reported valuation).
- It has raised $4.2M.
- Notable investors include European Innovation Council, European Commission, CVX Ventures, Farvatn Venture, Innovasjon Norge — 12 tracked in total.
- Status: Privately Held (backing).
Picterus's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Picterus: the Monday email on marks, rounds and moves
Picterus funding rounds
No funding rounds for Picterus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Picterus
12+Membership and data by Private Market View
Picterus valuation
Picterus's last reported valuation was $8.9 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Picterus investors
12 investors are on record for Picterus, including European Innovation Council, European Commission, CVX Ventures and Farvatn Venture.
About Picterus
Developer of a smartphone-based neonatal screening tool designed for early detection of jaundice in newborns. The company's platform utilizes a patented color calibration card and an app that ensures correct camera distance, positioning, and quality before capturing images for analysis, enabling healthcare professionals and caregivers with a safer alternative to visual inspection and supporting timely medical intervention for newborns when they are at risk of jaundice.
- Sector
- Healthcare
- HQ
- Trondheim, Norway
- Founded
- 2015
- Employees
- 29
- Website
- picterus.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.